Santhera Pharmaceuticals announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Raxone® (idebenone) for the treatment of Duchenne muscular dystrophy.
Following on from the success in West Yorkshire, we are planning on setting up more groups in an area near you and reaching out to individuals and families from all communities. If you want to be involved contact us today!
A huge thank you and good luck to the 16 runners from St George taking on the Vitality London 10,000 today for Muscular Dystrophy UK. St George has partnered with the charity since 2000, raising an incredible £414,000 to support our work which equals over 9000 hours of research! ... See MoreSee Less
At the Scottish research conference Dr Shuko Joseph, Clinical Research Fellow at the University of Glasgow, will present an update on the important research she has been leading to understand the effect of Duchenne muscular dystrophy on bone health.